Type 4 cyclic nucleotide phosphodiesterase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Overview
Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolytic destruction of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), to produce 5’-AMP and 5’-GMP, respectively. Type 4 cyclic nucleotide phosphodiesterases (PDE4) are a family of low km 3',5'-cyclic adenosine monophosphate (cAMP)-specific phosphodiesterases including at least 20 isozymes encoded by four genes (PDE4A, PDE4B, PDE4C, and PDE4D) in mammals. Because PDE4 isoforms exhibit widespread tissue distribution, perhaps more than any other PDE family, inhibition of PDE4 enzymes alters cAMP-signaling in many cells. The development of PDE4 inhibitors with improved therapeutic indexes has been a major focus of pharmaceutical research for the treatment of chronic inflammatory diseases.
Report Highlights
This segment of the Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Emerging Drugs
Further product details are provided in the report……..
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs.
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Overview
Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolytic destruction of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), to produce 5’-AMP and 5’-GMP, respectively. Type 4 cyclic nucleotide phosphodiesterases (PDE4) are a family of low km 3',5'-cyclic adenosine monophosphate (cAMP)-specific phosphodiesterases including at least 20 isozymes encoded by four genes (PDE4A, PDE4B, PDE4C, and PDE4D) in mammals. Because PDE4 isoforms exhibit widespread tissue distribution, perhaps more than any other PDE family, inhibition of PDE4 enzymes alters cAMP-signaling in many cells. The development of PDE4 inhibitors with improved therapeutic indexes has been a major focus of pharmaceutical research for the treatment of chronic inflammatory diseases.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors R&D. The therapies under development are focused on novel approaches for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors.
This segment of the Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Emerging Drugs
- Ensifentrine : Verona Pharma
- Difamilast: Otsuka Pharmaceutical
Further product details are provided in the report……..
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs.
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Report Insights
- Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs?
- How many Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Verona Pharma
- MediciNova
- Innovation Pharmaceuticals
- Otsuka Pharmaceutical
- Chiesi Farmaceutici
- BioTheryX
- AnnJi Pharmaceutical
- UNION Therapeutics
- MediciNova
- Amgen
- Arcutis Biotherapeutics
- Ensifentrine
- Ibudilast
- Brilacidin
- Difamilast
- Tanimilast
- BTX-2640
- AJ-503
- Research programme: phosphodiesterase type 4 inhibitors
- Tipelukast
- Apremilast
- Roflumilast topical
Introduction
Executive Summary
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Ensifentrine: Verona Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tanimilast: Chiesi Farmaceutici
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BTX-2640: BioTheryX
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Companies
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Products
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Unmet Needs
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Market Drivers and Barriers
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Future Perspectives and Conclusion
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Analyst Views
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Companies
Appendix
Executive Summary
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Ensifentrine: Verona Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tanimilast: Chiesi Farmaceutici
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BTX-2640: BioTheryX
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Companies
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Products
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Unmet Needs
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Market Drivers and Barriers
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Future Perspectives and Conclusion
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Analyst Views
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
